KT501 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1: 1

Top Sponsors

Kali Therapeutics, Inc.1

Indications

Rheumatoid Arthritis (RA1
Arthritis1

Other1 trial

A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.